About SYNIMMUNE
SYNIMMUNE is a Healthcare company based in Tubingen (Germany) founded in 2010, and was acquired by VERAXA in December 2023. German, early-stage biotech developing mono- and bi-specific antibodies for cancer treatment. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
SYNIMMUNE was founded in 2010 as a spin-off from the University of Tübingens Department of Immunology. Early-stage development of mono- and bispecific antibodies targets cancer therapies, with operations based in Tübingen, Germany. Over 6.4 million in grants has been secured from the German Ministry of Education and Research. The pipeline includes two FLT3-targeted candidates: FLYSYN, a chimeric IgG1 antibody in Phase 1, and TACSYN, a bispecific antibody in Phase 2.
- Headquarters Tubingen, Germany
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website synimmune.de/en
- Social LinkedIn
- Acquired by VERAXA (Dec 2023)
Investors in SYNIMMUNE
SYNIMMUNE has secured backing from 1 investor. Prominent investors backing the company include VERAXA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Antibody therapeutics for cancer treatment are developed via microfluidic screening. | 2017 | veraxa.com | Heidelberg, Germany |
Investor details for SYNIMMUNE
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of SYNIMMUNE
2 dated milestones of SYNIMMUNE across 13 years, from founding to its latest funding, stage changes and deals.
- Founded SYNIMMUNE is founded.
- Exit Acquired by VERAXA.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Synimmune
Complete news archive for SYNIMMUNE
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SYNIMMUNE
SYNIMMUNE was founded in 2010.
SYNIMMUNE is headquartered in Tubingen, Germany. It is registered at Tubingen, Baden-wurttemberg, Germany.
SYNIMMUNE was founded in 2010 as a spin-off from the University of Tübingens Department of Immunology. Early-stage development of mono- and bispecific antibodies targets cancer therapies, with operations based in Tübingen, Germany. Over 6.4 million in grants has been secured from the German Ministry of Education and Research. The pipeline includes two FLT3-targeted candidates: FLYSYN, a chimeric IgG1 antibody in Phase 1, and TACSYN, a bispecific antibody in Phase 2.
SYNIMMUNE has 1 investor. Key investors include VERAXA.
Yes. SYNIMMUNE was acquired by VERAXA in December 2023.